Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus.
Thromboxane and prostacyclin metabolite determinations (radioimmunoassay) were performed in obliterative atherosclerosis and in diabetes mellitus with microangiopathy. The shift of these metabolites to the thromboxane side could have been documented in both diseases. This phenomenon calls attention to an increased platelet activation and endothelial cell damage. In a third group patients received aspirin (500 mg on alternative days) which caused a marked inhibition of both thromboxane and prostacyclin production, measured this way. The possible role of altered balance of these two prostanoids in atherogenesis and diabetic angiopathy is discussed.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D001161:Arteriosclerosis / Q000097:blood* / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000097:blood* / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011451:Prostaglandin-Endoperoxide Synthases / Q000172:deficiency; D013928:Thromboxane A2 / Q000378:metabolism*; D013929:Thromboxane B2 / Q000097:blood
D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin